SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Novo Nordisk - ADR

Novo Nordisk A/S

Novo Nordisk is trending as the community discusses the implications of the company's recent Phase III trial failure for its Alzheimer's drug, with some investors expressing disappointment while others see it as an opportunity to buy. Despite the setback, there is optimism surrounding Novo Nordisk's position in the weight loss market, particularly with the potential upcoming approval of its oral Wegovy pill and comparison of CagriSema vs Zepbound study results.

Pony.ai, Inc. develops artificial intelligence-based robot designed for autonomous driving. The firm's software algorithms and infrastructure enables a vehicle to perceive its surroundings, predict what others will do, and maneuver itself accordingly. The company was founded by Jun Peng and Tian Cheng Lou in November 4, 2016 and is headquartered in Guangzhou, China.

Pony AI Inc. - ADR

Pony AI Inc

Pony AI is trending due to news of expanded robotaxi operations and partnerships, including a recent permit in Shanghai. The community is weighing the company's growth prospects against its financial performance, especially regarding profitability targets. Broader discussions involve comparing Pony AI to competitors in the autonomous driving space and assessing the impact of these developments on its market position.

Diginex Ltd. (Hong Kong) is a blockchain financial services and technology company. Its products include diginexESG, diginexLUMEN, diginexAPPRISE, diginexLUMEN Pro, and CSRD framework. The company was founded by Miles Christian Pelham on May 15, 2020 and is headquartered in London, the United Kingdom.

Diginex Ltd.

DGNX is trending due to its recent acquisition of The Remedy Project, sparking discussions about the company's expansion into human-rights remediation. The community is also actively analyzing potential trading strategies based on historical patterns of similar stocks. Options traders are closely monitoring put contracts, anticipating potential downside amidst the volatility.

WeRide, Inc. operates as an investment holding company. It engages in the sale of autonomous driving vehicles, primarily including robobuses, robotaxis, robosweepers and related sensor suites. The company was founded by Tony Xu Han and Yan Li in February 2017 and is headquartered in Guangzhou, China.

WeRide Inc. - ADR

WeRide is trending due to strong Q3 2025 earnings, highlighted by a 144.3% YoY revenue increase and significant growth in robotaxi revenue, with community members noting global expansion and regulatory milestones in the UAE and Switzerland. Investors are focused on WeRide's progress toward deploying hundreds of thousands of robotaxis by 2030 and its partnerships with companies like Bosch, Uber, and Grab. The conversation also includes comparisons to competitor Pony.ai, whose stock performance and institutional ownership are being weighed against WeRide's recent gains and expansion efforts.

Monad

Monad is trending as users discuss its upcoming launch and token distribution, particularly excitement around receiving tokens from the Coinbase presale. The community is actively speculating on potential price movements and strategies, with some comparing it to other recent launches. There's also discussion around the mainnet launch date.

JPMorgan Chase & Co. is a financial holding company, which engages in the provision of financial and investment banking services. It focuses on investment banking, financial services for consumers and small businesses, commercial banking, financial transaction processing, and asset management. It operates through the following segments: Consumer and Community Banking (CCB), Commercial and Investment Bank (CIB), Asset and Wealth Management (AWM), and Corporate. The CCB segment originates and services mortgage loans. The CIB segment makes markets and services clients across fixed income, foreign exchange, equities, and commodities. The AWM segment provides initial capital investments in products such as mutual funds and capital invested alongside third-party investors. The Corporate segment manages its liquidity, funding, capital, structural interest rate, and foreign exchange risks. The company was founded in 1799 and is headquartered in New York, NY.

JPMorgan Chase & Co.

JPMorgan Chase & Co

JPMorgan Chase is trending amid mixed sentiment, as discussions range from its ties to controversial figures to its evolving stance on cryptocurrency and potential competition with Bitcoin. The community is actively debating JPMorgan's investment strategies, alleged market manipulation, and the implications of its exploration of blockchain technology and stablecoins. Additionally, some traders are monitoring technical indicators to predict JPM's short-term price movements, while others are discussing potential investigations and regulatory scrutiny.

Alvotech is a biotechnology company, which engages in the development and manufacture of biosimilar medicines. The firm is focusing on the development of its product candidates. It operates through the following geographical segments: Europe, North America, Asia, and Other. The company was founded by Róbert Vilhelm Wessman in 2013 and is headquartered in Luxembourg.

Alvotech

Alvotech ($ALVO) is trending following the announcement of European approval for AVT03, a biosimilar to Prolia and Xgeva, used in bone disease treatment, sparking bullish sentiment. Despite some community concerns about cash flow and previous manufacturing setbacks, the biosimilar's approval and analyst upgrades are fueling optimism. Discussions center on the company's potential in the biosimilar market and strategic partnerships.

Shopify, Inc. is a global commerce company that provides essential internet infrastructure for commerce, offering trusted tools to start, scale, market, and run a retail business of any size. The Company's software enables merchants to run their business across all of their sales channels, including web and mobile storefronts, physical retail locations, social media storefronts and marketplaces. The Shopify platform provides merchants with a single view of their business across all of their sales channels and enables them to manage products and inventory, process orders and payments, fulfill and ship orders, build customer relationships, source products, leverage analytics and reporting and access financing, all from one integrated back office. The company was founded on September 28, 2004 and is headquartered in Ottawa, Canada.

Shopify Inc - Ordinary Shares - Class A (Sub Voting)

Shopify Inc

Shopify is trending as the stock price rises following news of its AI integration with Open AI, which is expected to enhance merchant and customer experiences, with some analysts predicting a significant price target increase. However, some community members are skeptical about the sustainability of Shopify's growth, citing competition and valuation concerns, while others point to the company's strong position in the e-commerce sector and potential for further gains.

Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the Biopharma segment, which comprises commercial operations and research, development and production activities relating to the specialty care, general medicines and vaccines franchises plus support and corporate functions, for all geographical territories. The company was founded in 1973 and is headquartered in Paris, France.

Sanofi - ADR

Sanofi-Aventis

Sanofi-Aventis ($SNY) is trending amid speculation surrounding potential acquisitions, particularly in the MASH and obesity spaces, with $ALT, $GUTS, and $IVA being mentioned as possible targets. Community discussions revolve around the company's pipeline expansion needs and potential partnerships, with some users highlighting data integrity concerns around one of the speculated targets. The broader context involves Sanofi's strategic moves to strengthen its immunology and vaccine portfolio.

mF International Ltd. is a holding company, which engages in the development and provision of financial trading solutions through its subsidiary. It offers real-time mission critical forex, bullion and commodities trading platform solutions, financial value-added services, mobile applications, and financial information for brokers and institutional clients via internet or platform as software as a service. The company was founded by Tai Wai Lam and Chi Weng Tam on June 15, 2022, and is headquartered in Hong Kong.

mF International Ltd - Ordinary Shares - Class A

mF International Ltd

MFI is trending due to its recent $500M private placement aimed at building a Bitcoin Cash treasury, fueling speculation about a potential pivot into crypto equity. Community members are discussing the involvement of a Chinese billionaire and the possibility of MFI becoming a major player in the crypto space. The stock's volatile price action and small float are contributing to the heightened interest.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Leede Jones Gab Weighs in on ProMIS Neurosciences, Inc.'s FY2024 Earnings (NASDAQ:PMN)

ProMIS Neurosciences, Inc. (NASDAQ:PMN - Free Report) - Leede Jones Gab cut their FY2024 EPS estimates for ProMIS Neurosciences in a research note issued to investors on Wednesday, April 3rd...

ProMIS Neurosciences, Inc. Expected to Earn FY2028 Earnings of $0.62 Per Share (NASDAQ:PMN)

ProMIS Neurosciences, Inc. (NASDAQ:PMN - Free Report) - Equities research analysts at Leede Jones Gab issued their FY2028 earnings per share (EPS) estimates for ProMIS Neurosciences in a research...

ProMIS Neurosciences to Present in Upcoming Investor Conferences in April

CAMBRIDGE, Massachusetts and TORONTO, Ontario, April 04, 2024 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a biotechnology company focused on the generation and development of...

ProMIS Neurosciences Announces Full Year 2023 Financial Results and Recent Highlights

Top-line data from first-in-human Phase 1a clinical trial of PMN310 as a treatment for Alzheimer's disease on track for mid-2024CAMBRIDGE, Massachusetts and TORONTO, Ontario, April 01, 2024 (GLOBE...

ProMIS Neurosciences Strengthens Global Intellectual Property Portfolio

Adds Key U.S. and International Patent Allowances to Further Protect the Company's Monoclonal Antibody Therapeutic for the Treatment of Alzheimer's DiseaseCAMBRIDGE, Massachusetts and TORONTO...

ProMIS Neurosciences to Present at the 2024 BIO CEO & Investor Conference

CAMBRIDGE, Massachusetts and TORONTO, Ontario, Feb. 22, 2024 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a biotechnology company focused on the generation and development of...

ProMIS Neurosciences Achieves Milestone in Development of Therapeutic Alpha-Synuclein Vaccine

Lead vaccine candidate selected for advancement against synucleinopathies including Multiple System Atrophy, Parkinson's disease and Dementia with Lewy bodiesCAMBRIDGE, Massachusetts and TORONTO...

ProMIS Neurosciences Issues Letter to Shareholders

TORONTO, Ontario and CAMBRIDGE, Massachusetts, Jan. 08, 2024 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Issues Letter to ShareholderProMIS Neurosciences Inc. (Nasdaq: PMN), a biotechnology company...

ProMIS Neurosciences, Inc. Announces Leadership Transition

Appoints Neil Warma, Industry Leader and ProMIS Board Member, as Interim Chief Executive OfficerCAMBRIDGE, Massachusetts and TORONTO, Ontario, Jan. 03, 2024 (GLOBE NEWSWIRE) -- ProMIS Neurosciences...

ProMIS Neurosciences, Inc. engages in the discovery and development of precision medicine solutions for early detection and effective treatment of neurodegenerative diseases. It focuses on the progression of Alzheimer's disease, amyotrophic lateral sclerosis, and Parkinson's disease. The company was founded by Neil Cashman and Vigen Nazarian on January 23, 2004 and is headquartered in Toronto, Canada.

PMN
ProMIS Neurosciences

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest PMN News

PMNProMIS Neurosciences